荷丹片对冠心病合并2型糖尿病患者血脂、炎症因子及氧化应激水平的影响

发布时间：2018-11-13 08:19

【摘要】：目的:探究荷丹片对冠心病合并2型糖尿病患者血脂、炎症因子及氧化应激水平的影响及安全性。方法:收集2013年7月-2015年11月我院收治的冠心病合并2型糖尿病患者118例,按随机数字表法分为观察组(63例)和对照组(55例)。对照组患者给予控制血糖、调节血脂、扩张血管、抗凝等常规治疗;观察组患者在对照组基础上餐前口服荷丹片1.46 g,tid。两组患者均连续治疗6个月。比较两组患者治疗前后血脂[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、血清炎症因子[肿瘤坏死因子α(TNF-α)、白细胞介素10(IL-10)、IL-6、超敏C反应蛋白(hs-CRP)]、血清氧化应激指标[丙二醛(MDA)、超氧化物歧化酶(SOD)、一氧化氮(NO)]水平及不良反应发生情况。结果:治疗前,两组患者血脂、炎症因子及氧化应激指标水平比较,差异均无统计学意义(P0.05);治疗后,两组患者TC、TG、LDL-C、TNF-α、IL-6、hs-CRP、MDA水平显著降低,IL-10、SOD、NO水平显著升高,且观察组上述指标均显著优于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:荷丹片能有效改善冠心病合并2型糖尿病患者血脂及血清炎症因子水平,减轻炎性损伤,降低氧自由基水平,增强机体抗氧化能力,减轻氧化应激损伤,且安全性较高。
[Abstract]:Aim: to investigate the effect and safety of Hedan tablets on serum lipids, inflammatory factors and oxidative stress in patients with coronary heart disease (CHD) complicated with type 2 diabetes. Methods: 118 cases of coronary heart disease complicated with type 2 diabetes were collected from July 2013 to November 2015 in our hospital. According to the method of random number table, they were divided into observation group (63 cases) and control group (55 cases). The patients in the control group were given routine treatment such as controlling blood glucose, regulating blood lipids, dilating blood vessels and anticoagulant, while the patients in the observation group were given 1.46 g Hedan tablet before meal on the basis of the control group. The patients in both groups were treated continuously for 6 months. Serum lipids [total cholesterol (TC), triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)] were compared between the two groups before and after treatment. Serum inflammatory factor [tumor necrosis factor 伪 (TNF- 伪), interleukin 10 (IL-10), IL-6, hypersensitive C-reactive protein (hs-CRP)], serum oxidative stress index [malondialdehyde (MDA), superoxide dismutase (SOD),] The level of nitric oxide (NO) and the occurrence of adverse reactions. Results: before treatment, the levels of blood lipids, inflammatory factors and oxidative stress were not significantly different between the two groups (P0.05). After treatment, the levels of TC,TG,LDL-C,TNF- 伪, IL-6,hs-CRP,MDA and IL-10,SOD,NO in the two groups were significantly decreased, and the above indexes in the observation group were significantly better than those in the control group. The difference was statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: Hedan tablet can effectively improve blood lipids and serum inflammatory factors in patients with coronary heart disease and type 2 diabetes mellitus, reduce inflammatory injury, reduce oxygen free radicals, enhance the ability of body anti-oxidation, reduce oxidative stress injury, and have higher safety.
【作者单位】：漯河市中心医院药学部;漯河市中心医院内分泌代谢科;
【分类号】：R541.4;R587.1

【相似文献】